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Abstract
Background: Tpl2/Cot oncogene has been identified in murine T-cell lymphomas as a target of
MoMuLV insertion. Animal and tissue culture studies have shown that Tpl2/Cot is involved in
interleukin-2 (IL-2) and tumor necrosis factor-α (TNF-α) production by T-cells contributing to T-
cell proliferation. In the present report we examined a series of 12 adult patients with various T-
cell malignancies, all with predominant leukemic expression in the periphery, for the expression of
Tpl2/Cot oncogene in order to determine a possible involvement of Tpl2/Cot in the pathogenesis
of these neoplasms.
Results: Our results showed that Tpl2/Cot was overexpressed in all four patients with Large
Granular Lymphocyte proliferative disorders (LGL-PDs) but in none of the remaining eight patients
with other T-cell neoplasias. Interestingly, three of the LGL-PD patients displayed neutropenia, one
in association with sarcoidosis. Serum TNF-α levels were increased in all Tpl2/Cot overexpressing
patients while serum IL-2 was undetectable in all subjects studied. Genomic DNA analysis revealed
no DNA amplification at the Tpl2/Cot locus in any of the samples analyzed.
Conclusions: We conclude that Tpl2/Cot, a gene extensively studied in animal and tissue culture
T-cell models may be also involved in the development of human LGL-PD and may have a role in
the pathogenesis of immune manifestations associated with these diseases. This is the first report
implicating Tpl2/Cot in human T-cell neoplasias and provides a novel molecular event in the
development of LGL-PDs.
Background
Cells may transform to a malignant phenotype following
accumulation of distinct genetic events that result in
altered protein expression pattern, thus facilitating uncon-
trolled proliferation. Such genetic events target specific
oncogenes that act in concert to provide the malignant
phenotype.
Tpl2/Cot oncogene was initially cloned as a MoMuLV pro-
viral integration locus in murine T-cell lymphoma cells,
resulting in its carboxy-terminal truncation[1,2]. Expres-
sion of the truncated form of Tpl2 as a transgene in T-cells
under the control of the lck promoter in mice results in
rapid development of T-cell lymphomas [3]. Expression
of Tpl2 is associated with T-cell activation. Overexpression
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of the wild type Tpl2 in the Jurkat T-cell leukemia cell line
results in NFkB and NFAT activation and subsequent IL-2
and TNF-α expression [4-7]. In the CTLL2 IL-2 dependent
cell line Tpl2 promotes cell proliferation by activating
E2F-dependent transcription [8]. Tpl2/Cot is, therefore,
tightly associated with T-cell neoplasms and T-cell activa-
tion and proliferation.
Studies in human tumor specimens have shown that
Tpl2/Cot is overexpressed in early stage breast cancer [9],
in EBV-related Hodgkin lymphomas and nasopharyngeal
carcinomas [10] and occasionally in gastric and colon
adenocarcinomas [11]. To our knowledge, no available
data exist on human hematologic neoplasias, other than
Hodgkin lymphoma.
Given the compelling evidence of the importance of Tpl2/
Cot in experimental and tissue culture models of T-cell
neoplasias, we designed a study to investigate possible
involvement of Tpl2/Cot in the pathogenesis of human T-
cell neoplasias. Specifically, we studied 12 adults with var-
ious T-cell neoplasias to obtain a broad spectrum of T-cell
malignancies, all with predominant leukemic expression,
and examined whether Tpl2/Cot expression is deregulated
in the transformed cells. The expression levels of Tpl2/Cot
were quantitated by SybrGreen real-time RT-PCR using
three different quantitation approaches (standard
curve[12], absolute fluorescence increase [13] and the
M.W.Pfaffl method [14]) as well as the conventional
semi-quantitative RT-PCR.
Results
Evaluation of Tpl2/Cot mRNA expression in T-cell 
neoplasias
To determine the levels of expression of Tpl2/Cot mRNA
we first established and validated a real time PCR
approach. Melting curves showed that there were no by-
products in both Tpl2/Cot and GAPDH reactions (Figure
1B). CVs of mean triplicate Ct (threshold cycle) ranged
from 0.1% to 0.92% which account for a low intra-assay
variability. A series of five 10 to 20-fold dilutions of a
standard cDNA from different cDNA preparations were
also run multiple times to determine primer efficiencies.
Linear regression analysis of the standard curves [mean Ct
plotted against the log(RNA input)] showed high linear-
ity, with regression coefficients greater than 0.997 (Figure
1A). We used the standard curve slope in the equation
(1) E = 10-1/slope
to calculate the mean efficiency of Tpl2/Cot and GAPDH
primers. The slopes were almost equal (from -3.59 to -
3.62) for both primers which showed that we could use
the Pfaffl method [14] without the need of a standard
curve in every set of reactions. Specifically, to determine
the ratio (R) of the normalized Tpl-2/Cot expression of
sample vs control we used the equation
where Etarget and Eref are the Efficiencies of the target
(Tpl2) and reference genes(GAPDH) respectively which
both were equal to a mean of 1.89 and ÄCt is the differ-
ence between the mean Ct of control cDNA(CTR) and
patient cDNA (Sample). To confirm our results we also
tried the Absolute Fluorescence Increase method using the
LinRegPCR software v.7.5 which measures the actual effi-
ciency of each amplification curve by fitting its linear part
in a simulation plot of the Log (fluorescence) versus Cycle
and calculates the efficiency from the slope of a linear
regression model of the simulation curve [13]. As control
we used triplicates of cDNA from 3 healthy individuals,
for which we calculated the mean Ct. The control samples
were representative among 22 control specimens with
similar values. Results were similar to those obtained by
the Standard Curve method [12] (data not shown).
A total of 12 adult samples with T- and NK-cell neoplasias
were analyzed according to the described method. They
all had leukemic expression in the periphery. Morphology
was assessed by light microscopy on peripheral blood
smears, including measurement of absolute LGL number.
Four out of twelve (33%) patients tested markedly overex-
pressed Tpl2/Cot (p = 0.034), as determined by either
conventional RT-PCR or real-time qPCR (Tables 2 and 3,
Figure 2). Interestingly, all the Tpl2/Cot overexpressing
patients had LGL-PD, three with the phenotype of CD3+
T-LGL leukemia and one with the CD3- pattern of chronic
NK-lymphocytosis. Three of these patients displayed neu-
tropenia not attributable to BM infiltration, one in associ-
ation with sarcoidosis (Table 1). The fourth patient with
monoclonal T-LGL lymphocytosis had a co-current cuta-
neous T-cell lymphoma which, during follow-up,
demanded systemic chemotherapy.
Evaluation of serum TNF-α and IL-2 levels
Overexpression of Tpl2/Cot in Jurkat T-cells induces TNF-
α expression [7]. Tpl2 also regulates TNF-α expression in
macrophages by activating ERK and thus controlling the
posttranscriptional modification of the TNF-α mRNA,
which is necessary for its export from the nucleus [15].
We, therefore, evaluated serum TNF-α levels in all patients
studied. In order to have an internal negative control in
the study we analyzed 8 samples from normal blood
donors. The mean TNF-α concentration in patient sera
was 2.37 ± 1.4 pg/ml with a range between 1.2 pg/ml and
6.2 pg/ml, while in the control group it was 0.6 ± 0.2 pg/
m. The mean patient TNF-α value was statistically signifi-
cant higher than the respective of the healthy controls (p
(2) R
(Etarget)
(Eref)
Ct(meanCTR-meanSample)
Ct(meanCTR-me =
∆
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= 0.002), as was TNF-α in the LGL-PD group alone com-
pared to the control group (p = 0.006). It is of interest that
the patient with chronic NK-lymphocytosis and neutrope-
nia displayed the highest TNF-α value (6.2 pg/ml) that
was associated with the highest Tpl2/Cot expression (5.2
fold compared to control) (Table 3) suggesting a relation-
ship between Tpl2/Cot overexpression and TNF-α over-
production in this patient. There was no difference in
Real-Time PCR validation Figure 1
Real-Time PCR validation A. Serial dilutions of a standard cDNA duplicates for the construction of standard curves for 
GAPDH and Tpl2/Cot. The curve slopes shown on the upper right corner of each plot are -3.61 and -3.59 respectively. Black 
arrows correspond to dilution 1:10; white arrows to 1:20; left-pointed arrow is NTC (no-template control). X-axes represent 
the Log of the dilution factor, Y-axes the mean Ct of duplicates. B. Dissociation (melting) curve of the PCR products, showing 
a peak at 81.7°C for both Tpl2/Cot(black arrow) and GAPDH(white arrow), while NTCs have either no peak or a peak at a 
much lower temperature (thin arrow).
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TNF-α levels between the group of LGL-PD patients and
the group of patients with the remaining T-cell other neo-
plasias (p = 0,392).
Tpl2/Cot overexpression in Jurkat and EL-4 T-cells
induces IL-2 secretion in culture. We, therefore, examined
the expression levels of IL-2 in the sera from the 12
patients studied and 8 control samples. No circulating IL-
2 was detected in the sera of the patients or the control
donors (data not shown).
Overexpression of Tpl2/Cot in LGL-PD is not associated 
with gene amplification
Overexpression of Tpl2/Cot in human breast cancer has
been associated with amplification of the tpl2 genomic
locus [9]. We, thus, evaluated whether the overexpression
of Tpl2/Cot in T-cell malignancies is associated with
amplification of the genomic tpl2 locus. For this purpose
genomic DNA was isolated from PBMCs of the same
patients and part of the genomic tpl2 locus was amplified
using multiplex PCR. As reference gene we used the IFN-γ
gene. The results showed a similar tpl2/IFN-γ ratio in all
cases (Figure 3) indicating that overexpression of Tpl2/
Cot in LGL-PDs is not due to gene amplification.
Discussion
Experimental data based on in vitro and animal model
have shown that Tpl2/Cot is an important regulator in the
transduction of signals leading to T-cell activation [16].
Overexpression of this kinase results in increased prolifer-
ation of T-cells by activating E2F-dependent transcrip-
tional activity [8]. A truncated form present in rodents
exhibits increased catalytic activity, and when overex-
prerssed as a T-cell-specific transgene in mice it induces
tumors within 3–9 months [3]. Tpl2/Cot activates the
transcription factors NFAT and NFkB in T-cells, which
drive the transcription of several cytokine genes such as IL-
2 and TNF-α [4,7]. In macrophages, Tpl2/Cot is essential
for the activation of ERK by LPS via TLR4 and the export
of TNF-α mRNA from the nucleus [15]. The preceding evi-
dence supports a possible involvement of Tpl2/Cot in
human T-cell neoplasias.
Investigation of Tpl2/Cot expression in human tumor
specimen has shown that it is occasionally overexpressed
Table 1: Patient characteristics
Patient 
no.
Disease Sex Age %T+NKcells/
PBMC
Disease state Co-existent conditions
1 SS F 88 87 PP
2 CTCL with monoclonal T- LGL lymphocytosis M 63 86 RD
3 T-LGL leykemia F 75 93 RD Neutropenia
4 MF M 91 71 RD
5 MF M 85 71 RD
6T L L F 3 5 7 7 R D
7 T-PLL M 85 67 RD Myositis
8 Chronic NK -lymphocytosis F 67 64 Stable for two years Neutropenia
9T - A L L M 1 6 9 5  L B R D
10 T-LGL leukaemia with reactive NK 
lymphocytosis
F 60 71 Stable for 10 years Sarcoidosis (past), neutropenia
11 PTCL secondary to MF M 52 85 PR
12 Pre-T-ALL M 37 95 LB RD
Abbreviations: SS, Sezary syndrome; CTCL, Cutaneous T cell Lymphoma; T-LGL, T-large granular lymphocyte; MF, Mucosis Fungoides; NK, natural 
killer cell; TLL, T-lymphoblastic lymphoma; T-PLL, T-Prolymphocytic leukemia; T-ALL, T-acute lymphoblastic leukemia; LB, Lymphoblast ;PP, 
primary progressive; RD, recently diagnosed; PR, partial response.
Table 2: Tpl-2/Cot expression in PBMC
Patient no. Tpl2-Norma Fold increase (R)b CV(%)-Rc
Ctr (n = 3) 0.04 ± 0.019 1.00 ± 0.119 45.3
1 0.02 ± 0.000 0.59 ± 0.009 1.6
2 0.13 ± 0.005 3.88 ± 0.149 3.8
3 0.13 ± 0.005 4.04 ± 0.143 3.5
4 0.02 ± 0.003 0.66 ± 0.092 13.9
5 0.04 ± 0.005 1.22 ± 0.092 11.8
6 0.06 ± 0.003 1.70 ± 0.085 5.0
7 0.06 ± 0.002 1.81 ± 0.076 4.2
8 0.17 ± 0.008 5.21 ± 0.251 4.8
9 0.01 ± 0.000 0.32 ± 0.007 2.2
10 0.16 ± 0.006 5.04 ± 0.194 3.8
11 0.04 ± 0.001 1.09 ± 0.037 3.4
12 0.04 ± 0.004 1.22 ± 0.108 8.9
a. Tpl2/Cot normalized to GAPDH by equation (3) in the text ± SD.
b. Tpl2/Cot-Norm (sample) ratio to Tpl2/Cot-Norm (control) by 
equation (2) in the text ± SD. Samples in which Tpl2/Cot is 
overexpressed are shown in bold.
c. % Coefficient variance of (R).Molecular Cancer 2004, 3:34 http://www.molecular-cancer.com/content/3/1/34
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in colon and gastric adenocarcinomas [11] and human
breast cancer tissues [9]. Tpl2/Cot overexpression has also
been detected in a hepatocellular carcinoma cell line [17]
and in patient tumor tissue from EBV-related Hodgkin
lymphomas and nasopharyngeal carcinomas[10]. In the
present study we analyzed peripheral blood from patients
with T- and NK-cell lymphoproliferative diseases at the
time where the patients were not receiving any treatment
and had profound leukemic expression in the periphery.
Out of the 12 cases analyzed, Tpl2/Cot was found
overexpressed in three T-LGL-leukemias and in one
chronic NK-lymphocytosis accounting for all four LGL-
PDs studied. These findings suggest that Tpl2/Cot deregu-
lation may be a defining molecular event for the develop-
ment of this type of neoplasias. Given the role of Tpl2/Cot
in T-cell proliferation via activation of E2F transcription
[8], overexpression of this kinase may contribute to neo-
plastic cell proliferation.
Table 3: Summary of the results
Patient no. Immunophenotype Serum TNF-α (pg/ml) Tpl2/Cot (fold increase)
1 CD3+, CD4+, CD7- 1.7 0.6
2 CD3+, CD8+, CD56+, CD57+, TCRαβ+1 . 9 3.9
3 CD3+, CD8+, CD16, 56-, CD57+, TCRαβ+1 . 8 4
4 CD3+, CD4+, CD5+, CD7+ 1.5 0.7
5 CD3+, CD4+, CD7- 1.9 1.2
6 TdT+, CD5+, CD2+ 2.5 1.7
7 CD3+CD4+CD25-TCRγ+ 3.8 1.8
8 CD2+, CD3-, CD16+, CD56-, CD57-, TCR- 6.2 5.2
9 TdT+, CD2+, CD3+, CD7+, CD4-, CD8- 2.6 0.3
10 2 populations: a) T-LGL CD3+, CD8+, CD56+, CD57+, TCR γ+ b) NK 
CD2+, CD3-, CD16, 56+, 57-
1.9 5
11 CD3+, CD4+, CD7-, CD25-, TCRαβ+ 1.2 1.1
12 TdT+, cCD3+, CD7+, CD4-CD8- 1.5 1.2
Tpl2/Cot mRNA expression in T-cell neoplasms Figure 2
Tpl2/Cot mRNA expression in T-cell neoplasms. Representative semi-quantitative RT PCR for Tpl-2 mRNA expression 
in patients and controls. A. Tpl2/Cot PCR product of 228 bp B. β-Actin PCR product of 214 bp. Samples no 2, 3, 8 and 10 are 
overexpressed compared to the control and correspond to the LGL-PD patients shown in Table 1.
300bp
200bp A.Tpl2/Cot
B. ȕ-ǹctin
200 bp
100 bp
Sample no.      10  3   7  12  6  2  11  8     Ctr CtrMolecular Cancer 2004, 3:34 http://www.molecular-cancer.com/content/3/1/34
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Large granular lymphocyte lymphoproliferative diseases
(LGL-PD) are relatively rare and not well defined disor-
ders, frequently associated with autoimmune diseases or
immune mediated manifestations such as rheumatoid
arthritis (pseudo-Felty syndrome [18]), RF positivity, neu-
tropenia and pure red cell aplasia [19,20]. They present
clinical, morphological and immunological distinct fea-
tures, resulting from chronic proliferation of CD3+ or
CD3- granular lymphocytes. In the CD3+ cases the prolif-
erating cells express CD8 and NK-associated surface anti-
gens such as CD16, the LGL-specific CD57 antigen and
CD45RA, and display also clonal rearrangement of the
TCR alpha-beta or, less often, gamma-delta chains, thus
representing cytotoxic effector T-cells[21]. The T-LGL
leukemias are by definition indolent, but there are rare
reports indicating evolution to high grade lymphoma
[22]. Limited data on recurrent chromosomal aberrations
exist [23,24]. In the rare CD3- cases the cells are TCR-,
CD2+, CD16+ and CD56+ representing, therefore, true
NK-cell proliferations corresponding to the aggressive NK-
cell leukemias or to the – usually benign – chronic NK-
lymphocytosis [19,20]. Lack of Tpl2/Cot gene amplifica-
tion in our LGL-PD patients indicate that overexpression
is either due to changes in the regulation of Tpl2/Cot gene
activation or mRNA stability. Such changes can be either
primary (i.e. mutations that affect the promoter or the
mRNA stability) or secondary (i.e. activation of transcrip-
tion factors that affect the Tpl2/Cot promoter or signaling
molecules that affect the stability of its mRNA).
There is accumulating evidence suggesting that patients
with LGL-PDs display frequently immune manifestations
and increased TNFα production by the neoplastic T-cells
has been reported to play a role in their pathogene-
sis[20,25]. Interestingly, three of our LGL-PD patients dis-
played neutropenia not attributable to BM infiltration
while one of these patients displayed also sarcoidosis.
Evaluation of circulating TNF-α level in the patients
showed that the highest TNF-α value was found in the
LGL-PD patients that displayed also the highest Tpl2/Cot
expression among the subjects studied. These findings are
in agreement with previous reports demonstrating that
Tpl2/Cot is involved in TNF-α expression and secretion
[7,15] while provide evidence for a causal relationship
between the Tpl2/Cot overexpression, the TNF-α overpro-
duction and the pathogenesis of neutropenia in LGL-PD
patients [25]. TNF-α was increased in the sera of patients
where Tpl2/Cot expression was not elevated, indicating
that in these patients TNF-α may be upregulated via alter-
native pathways not associated with overexpression of
Tpl2/Cot.
Conclusions
In conclusion, data from the present study suggest that
Tpl2/Cot overexpression may have a role in the develop-
ment of certain types of human T-cell neoplasms thus
confirming experimental data on animal and tissue cul-
ture models for the role of Tpl2/Cot in T-cell
malignancies.
Methods
Patients
Peripheral blood samples from 12 adults aged 16–88
years (median age 64 years) with various T- and NK-cell
neoplasias with peripheral blood leukemic expression
were collected during a two-year time period. Patients
with signs of infection or recently subjected to cytotoxic
therapy were excluded from the study. Diagnosis was
based on morphological, immunophenotypic and
genomic studies and histological findings of bone mar-
row and/or lymph node biopsies and disease was classi-
fied according to the WHO classification [26]. There were
three patients with T-LGL leukemia, one patient with
chronic NK lymphocytosis, one patient with Sezary syn-
drome (SS), two patients with Mucosis Fungoides (MF),
one patient with T-Prolymphocytic Leukemia (T-PLL),
The tpl2/cot genomic locus is not amplified in the T-cell neoplasms analyzed Figure 3
The tpl2/cot genomic locus is not amplified in the T-cell neoplasms analyzed. Multiplex PCR for the quantification of 
the Tpl-2/Cot gene load, relative to IFN-γ gene in patient and control DNA: tpl2/cot PCR product detected at 139 bp; IFN-γ PCR 
product at 250 bp. No significant difference between samples is evident.Molecular Cancer 2004, 3:34 http://www.molecular-cancer.com/content/3/1/34
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two patients with T-acute Lymphoblastic Leukemia (T-
ALL), one patient with T-lymphoblastic Lymphoma (TLL)
and one patient with Peripheral T-Cell Lymphoma
(PTCL) secondary to MF. Detailed patient characteristics
are presented in Table 1. Complete blood counts and flow
cytometric analysis of peripheral blood lymphocytes were
performed at the day of blood collection for the molecular
study. In addition, patient sera were obtained by centrifu-
gation of 4 ml of non-anticoagulated blood at 3000 rpm
for 10 min and were stored at -80°C for IL-2 and TNF-α
measurement. Peripheral blood specimens from 22
healthy volunteers age- and sex-matched with the patients
were collected and used as controls. This research project
was subjected to and approved by the Ethics Committee
of the University Hospital of Heraclion.
Peripheral Blood Mononuclear Cell isolation and RNA 
extraction
Peripheral blood mononuclear cells (PBMC) were iso-
lated from 9 ml of fresh EDTA-K3 anti-coagulated periph-
eral blood samples by Lymphoprep density centrifugation
(Nycomed Pharma AS, Norway). PBMCs were immedi-
ately lyzed in suitable volume of Trizol LS reagent (Invit-
rogen, UK) and mRNA was isolated according to the
manufacturers' protocol. An aliquot of 1 µg of total RNA
was treated with 1 IU DNase I, Amplification Grade (Inv-
itrogen, UK) to eliminate any traces of genomic DNA.
Semi-quantitative RT-PCR
First strand cDNA was synthesized by reverse transcription
of 1 µg total RNA using the Thermoscript™ RT kit (Invitro-
gen, UK). 0.8 µl of cDNA were amplified in a 20 µL PCR
reaction containing 250 nM of each primer, 200 nM
dNTPs, 0.5 IU Taq polymerase and 2 µl of 10X reaction
buffer (Platinum Taq DNA Polymerase kit, Invitrogen,
UK). Reactions were first optimized for annealing temper-
ature, Mg and primer concentration (data not shown).
Primers for Tpl2/Cot detection were derived from exons 3
and 4 of the human Tpl2/Cot gene (Genbank accession
no: AL547407), spanning an 8.5 kb intron to prevent co-
current genomic DNA amplification and their sequences
were: forward 5'-CAG TAA TCA AAA CGA TGA GCG TTC
TAA-3', reverse 5'-GAA CAT CGG AAT CTA TTT GGT AAC
GTC-3' producing a 228 bp-length amplicon. For normal-
ization of mRNA input differences human beta actin
mRNA (Genbank accession no: BC013835) was detected
using the following primers: forward 5'-CCG GCC AGC
CAG GTC CAG A-3', reverse 5'-CAA GGC CAA CCG CGA
GAA GAT G-3', amplifying a 214 bp cDNA fragment. In
each reaction two negative controls were included by
either omitting reverse transcriptase at the RT step or
cDNA template respectively.
PCR reactions were performed on a thermal cycler (PTC-
200 MJ Reasearch with heated lid) and repeated 3 times
with different cDNAs from the same mRNA. Expression of
Tpl2/Cot was determined by semi-quantitative, relative
RT-PCR. An amplification curve for each gene was
acquired by performing the reaction with increasing
number of PCR annealing cycles to identify the exponen-
tial phase of the reaction. The thermocycling parameters
were as follows: initial denaturation at 94°C for 5 min fol-
lowed by 34 for Tpl2 or 23 for actin cycles at 94°C for 30
sec, 54°C for 30 sec, 72°C for 30 sec and a final extension
at 72°C for 7 min.
The RT-PCR products were analysed by electrophoresis in
a 2.5% agarose gel, stained with 0.2 µg/ml ethidium bro-
mide and visualized in a UVP transiluminator (Gel Doc
1000 Bio Rad). The band intensity was analysed by a den-
sitometric image analysis system (TINA scan v2.07) and
the results were expressed as a ratio between Tpl2/Cot and
β-actin band intensity.
Real-time PCR
Primers for real-time PCR were designed with the Primer
Express Software v.2 (Applied Biosystems) and selected so
that they amplify a region of no more than 150 bp, they
have similar GC content, same Tm, no more than 3 G or
C's at the 3' end and no secondary structure formation. To
exclude primers with more than 3 consecutive comple-
mentary bases between them we used Qiagen Oligo Anal-
ysis & Plotting Tool (Qiagen, Germany). Primers forTpl2/
Cot annealed to exons 6–7 and their sequences were: for-
ward 5'-TCC TAA GGA CCT CCG AGG AAC-3', reverse 5'-
CCC AGG CTG TAG ATG TCT GCT-3', amplifying a 93 bp
region. GAPDH was used as a reference gene to compen-
sate for mRNA input differences. Primers for GAPDH
derived from exons 2–3 (Genbank accession no:
BC023632) and their sequences were: forward 5'-GGA
AGG TGA AGG TCG GAG TCA-3', reverse 5'-GTC ATT
GAT GGC AAC AAT ATC CAC T-3', amplifying a 101 bp
region.
Primer concentration, cDNA dilution, Mg concentration
and annealing temperature were optimized so that a max-
imum fluorescent signal with no inhibition from RT com-
ponents and a similar reaction yield from both primer sets
could be obtained. For the real-time PCR study cDNA
from first strand synthesis treated with RNase H for 20' at
37°C was diluted 1:20 with DNAse-free water and 5 µl
were used in a 20-µl reaction mixture consisting of 10.4 µl
2x SybrGreen PCR Master mix, 6 mM final concentration
of MgCl2 and 500 nM of the Tpl2/Cot primers or 100 nM
of GAPDH primers. Reactions were carried out using an
ABI Prism 7000 sequence detector (Applied Biosystems,
Foster City, CA, USA) according to manufacturer's instruc-
tions. The thermal profile used consisted of 2 min at
50°C,10 min at 95°C and 40 repeats of denaturation at
95°C for 15 sec and annealing-extension-fluorescenceMolecular Cancer 2004, 3:34 http://www.molecular-cancer.com/content/3/1/34
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data acquisition at 60°C for 1 min. A post-PCR Melting
Curve Analysis was performed by a 20-min slow ramp
from 60° to 95°C to confirm that there were no by-prod-
ucts. Samples were run in a 3% agarose gel after the end of
reaction to confirm specificity. All samples were run in
triplicates and two negative controls with either no reverse
transcriptase or no cDNA template were included. Reac-
tion was repeated twice in different days to estimate inter-
assay variation. Results were analyzed using the ABI Prism
7000 SDS software (v.1.1, Applied Biosystems) and Excel
for further quantitative study.
DNA extraction and multiplex PCR
To detect possible gene amplification in cases with Tpl2/
Cot overexpression we used a multiplex DNA PCR proto-
col with interferon-γ (IFN-γ) as a reference gene amplified
at the same reaction tube. High molecular weight DNA
was isolated from PBMC by proteinase K digestion and
phenol chloroform extraction with ethanol precipitation
and diluted in TE buffer. The primers for Tpl2/Cot were:
forward 5'-GCG ACG GAT TGA GGT TTG-3', reverse 5'-
GCG TTT CAG GCG TAT GGA-3' amplifying a 139 bp
region of intron 1(Genbank accession no.AY309013) and
the primers for IFN-γ were: forward 5'-ATG CAG GTC ATT
CAG ATG TAG C-3', reverse 5'-TTG GAT GCT CTG GTC
ATC TTT A-3' amplifying a 250 bp fragment containing
intron and exon sequences between exons 2–3 (Genbank
accession no: J00219). 50 ng of DNA were used in a 20 µl
reaction containing 10 µl Platinum qPCR Supermix-UDG
(Invitrogen, UK), 250 nM Tpl2/Cot primers and 100 nM
IFNγ primers. The number of amplification cycles was
adjusted so that the reaction terminated at the middle of
the exponential phase of both products (data not shown).
The thermal profile consisted of a denaturation step at
95° for 10 min, followed by 29 repeats at 95°C for 15 sec,
58°C for 30 sec and 72°C for 30 sec and a final extension
at 72°C for 7 min. PCR products were analysed in a 3%
agarose gel, visualized and scanned as described earlier
and the Cot/IFNγ ratio was determined.
Peripheral blood lymphocyte immunophenotype and 
assessment of T-cell clonality
Two-color flow cytometry was used for the analysis of
peripheral blood lymphocyte subpopulations. In brief,
100 µL aliquots of EDTA-anticoagulated peripheral blood
samples were surface stained with each of the following
PE- or FITC-conjugated mouse antihuman monoclonal
antibodies: anti-CD2, anti-CD3, anti-CD4, anti-CD8,
anti-CD5, anti-CD7, anti-CD16, anti-CD56, anti-CD57,
anti-CD19, anti-CD25, anti-CD11b, anti-CD79a, anti-
FMC7 and anti-HLA-DR (Beckman Coulter, France). Cells
were also stained for intracellular Terminal deoxy-trans-
ferase (TdT) (Beckman Coulter) and CD3 using the
IntraPrep intracellular staining kit (Beckman Coulter). PE-
or FITC-conjugated mouse IgG of appropriate isotype
served as negative controls. Following 30 min incubation
at room temperature and two washes with phosphate
buffer saline (PBS)-1% fetal bovine serum (FBS)-0.05%
azide, contaminating red cells were lysed with 0.12%
formic acid and samples were fixed in 0.2% parafol-
madeyde using the Q-prep reagent system (Coulter, Lou-
ton, England). Analysis on 10,000 events was performed
in an Epics Elite model flow cytometer (Coulter) in the
lymphocyte gate.
Clonality assessment of peripheral blood T-cells was per-
formed by analysing quantitatively different variable
regions of the T-cell receptor (TCR) β chain (Vβ reper-
toire) of CD3+ cells by means of flow cytometry using the
IOTest Beta Mark kit (Beckman Coulter), according to the
manufacturer's instructions [27]. T-cell clonality
assessment was also performed by PCR analysis using
primers for the TCR V(D)J junction in PBMC derived
DNA, according to standard methods in a reference
laboratory.
ELISA
TNF-α concentration was determined using the High Sen-
sitivity human TNF-α ELISA kit (R&D, USA) or the IL-2
ELISA kit (R&D, USA) according to the manufacturer's
instruction. According to the manufacturer, the sensitivity
of these assays are 0.12 pg/ml and 7 pg/ml respectively.
Statistical analysis
The comparison of Tpl2/Cot mRNA expression between
patient and control samples was performed by means of
the nonparametric Mann-Whitney U test using as varia-
bles the mean normalized Tpl-2 expression of each sam-
ple and control, described by the equation
(3) Tpl-2 norm = (E)-(mean CtTpl2-meanCtGAPDH)
where E is the mean common efficiency of the reference
and target gene that we calculated (E = 1.89, see section
Results)[14]. The Mann-Whitney U test was also used for
the comparison of the TNF a and IL-2 levels between the
Tpl-2 overexpressing patients, the controls and the non-
overexpressing patients.
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